NOW Foods Ashwagandha 450 mg Review

It's the half-tier. KSM-66 is contracted to 5% withanolides; generic 'ashwagandha root' powder runs 0.5-1.5%. NOW Foods at 2.5% sits between the two — better than raw root, but exactly half the standardisation density of KSM-66. A 450 mg cap at 2.5% delivers ~11 mg withanolides; a 600 mg KSM-66 cap delivers ~30 mg. To match the Wankhede 2015 trial active load you'd need ~2.5 caps/day of NOW (~1100 mg extract = ~28 mg withanolides), which moves the price toward $25/month — losing the budget advantage. The 2.5% standardisation is real and disclosed (most household generic brands don't even publish the %), but it's not a clinical-grade replacement for the patent.

Reputation-wise, yes — but the label only confirms part of that story. NOW is widely reported to run one of the larger in-house analytical chemistry setups in the supplement world (HPLC, ICP-MS, microbial assay lines), testing incoming raw material and finished product before release. What the label itself shows is more modest: the facility carries Intertek GMP certification (the globe seal on the back panel) — that's the only third-party facility certification the bottle or its photos display. An earlier version of this review claimed the facility was 'NSF-registered'; no NSF mark appears anywhere on the label or in the product photos, so that claim has been removed. NOW also publishes that they reject 20-25% of incoming ashwagandha lots for not meeting their specs, which is a genuinely transparent number for the household tier. The QC pedigree is real as far as it's disclosed; what's not real is treating unconfirmed reputation, or a certification the label doesn't show, as a substitute for the patent-extract trial evidence.

2 caps if you want to approximate the trial-relevant withanolide load. 1 cap = 450 mg extract = ~11 mg withanolides, which is roughly the low-dose arm of Salve 2019 (250 mg KSM-66 = ~12.5 mg withanolides) but well below the testosterone-trial loading. 2 caps = ~22 mg withanolides, approaching the 30 mg load of a standard KSM-66 600 mg trial dose. For cortisol/sleep endpoints 1 cap may be enough; for testosterone-endpoint protocols 2 caps is closer to the trial active dose. Both AM with food. At 2 caps/day the 90-cap bottle becomes a 45-day supply ($20/month effective) — at which point Nutricost KSM-66 at $14/month for a full 60-day supply at trial-exact dose is the better deal.

Two reasons. First, NOW's supply-chain model is built on in-house specification — they contract their own withanolide standardisation directly with raw-material suppliers rather than licensing a patent. Second, the KSM-66 license adds cost that breaks NOW's value-tier positioning ($10/month at 90 caps would become ~$18-22 if they paid Ixoreal's licensing). NOW Foods deliberately competes on QC discipline + price floor, not on patent provenance. The trade-off is real: you get a brand you trust at a price that's hard to beat, but you don't get the trial-grade standardisation that the published evidence base is built on.

NOW Foods is a different category despite similar shelf prices. Nature's Bounty's 1000 mg whole-root capsules are non-standardised — the label has no withanolide percentage and the content can vary 10-20× lot to lot. NOW Foods at 2.5% withanolides has actual standardisation, in-house QC verification of that 2.5%, and an Intertek GMP-certified manufacturing facility. The $1/month difference between the two ($9 Nature's Bounty vs $10 NOW) is the difference between buying a brand that publishes its standardisation spec and one that ships unverified ground root powder. NOW is in a different league at the household tier.

Three specific cases: (1) You're an offline shopper — NOW is stocked at every Sprouts, Whole Foods, Vitamin Shoppe, and most independent health stores; you can grab it on a Sunday without waiting for Amazon. (2) You're stack-building and ashwagandha is a secondary support, not the primary endpoint — at 1 cap/day for cortisol nudge, $10/month is a reasonable budget allocation. (3) You're testing tolerance/sedation response before committing to a $22+ KSM-66 protocol — NOW is the cheapest way to validate you're not in the 5-10% of users who react poorly. For primary testosterone-endpoint protocols, go KSM-66 (Nutricost at $14 if budget is tight, Double Wood at $22 if not).

Probably mildly. At 2 caps/day = ~22 mg withanolides, you're at ~75% of the KSM-66 600 mg trial active load. Some effect on cortisol and downstream T is plausible — Salve 2019 saw cortisol fall at 250 mg KSM-66 (~12.5 mg withanolides), about half this dose. But the KSM-66 testosterone evidence (Wankhede 2015) is built specifically on the 30 mg withanolide load from 600 mg KSM-66. You'll likely see modest cortisol movement at 2 caps NOW/day; whether that's enough to shift free T panels in 8 weeks is responder-dependent. Honest framing: pick this for stress/sleep secondary effects, not as the primary testosterone protocol bottle.

1. [1] Lopresti 2019 (stress) PMID 31517876 — An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. 60 stressed adults took 240 mg of Shoden or placebo once daily for 60 days. Anxiety scores (HAM-A) fell more than on placebo, as did morning cortisol and DHEA-S. Sleep was not an outcome. The extract was Shoden, not KSM-66. It is no dose benchmark for this bottle.
2. [2] Wankhede 2015 PMID 26609282 — Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. 600 mg/day KSM-66 (= 30 mg withanolides) for 8 weeks in resistance-trained men measured serum testosterone +96 ng/dL vs +18 placebo. Cited as the testosterone-trial active load NOW Foods at 1 cap/day undershoots (~11 mg actives = 37% of trial dose) — explains why 2 caps/day is needed to approximate the T-trial protocol.
3. [3] Lopresti 2019 (testosterone) PMID 30854916 — A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males. 57 overweight men aged 40-70 took Shoden (21 mg withanolide glycosides a day) or placebo for 8 weeks each in a crossover trial. Testosterone rose 14.7% and DHEA-S 18% more than on placebo; cortisol, fatigue and sexual well-being did not differ. The extract was Shoden, not KSM-66.
4. [4] Chandrasekhar 2012 PMID 23439798 — A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. 600 mg/day KSM-66 for 60 days in chronically stressed adults reduced perceived stress -44% and morning cortisol -27.9% vs placebo. Cited as the patent-extract benchmark — NOW Foods at 2.5% generic extract doesn't have a parallel trial.
5. [5] Salve 2019 PMID 32021735 — Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. 60 stressed adults took 250 or 600 mg a day of ashwagandha root extract, or a placebo, for 8 weeks. Perceived stress and serum cortisol fell at both doses. Sleep quality improved compared with placebo. It used a high-concentration root extract, which NOW's generic 2.5% extract does not directly match.
6. [6] Auddy 2008 — A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: a double-blind, randomized, placebo-controlled study. 125-250 mg/day Sensoril (10% withanolides) reduced cortisol -24.2% and raised DHEA-S +32%. Cited as the Sensoril benchmark — comparison context showing how patent-grade standardisation density (10% Sensoril vs 2.5% NOW Foods) changes the dose-response math.